Cargando…
Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
SIMPLE SUMMARY: Given that most patients with MSS mCRC do not respond to immunotherapy agents or do not have durable clinical responses, there is an unmet clinical need to obtain predictors of response to immunotherapy and rational immunotherapy-based combination therapies for this entity. In this r...
Autores principales: | Baraibar, Iosune, Mirallas, Oriol, Saoudi, Nadia, Ros, Javier, Salvà, Francesc, Tabernero, Josep, Élez, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699573/ https://www.ncbi.nlm.nih.gov/pubmed/34944931 http://dx.doi.org/10.3390/cancers13246311 |
Ejemplares similares
-
Encorafenib plus cetuximab for the treatment of
BRAF-V600E-mutated metastatic colorectal
cancer
por: Ros, Javier, et al.
Publicado: (2022) -
Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
por: Ros, Javier, et al.
Publicado: (2023) -
Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
por: Ros, Javier, et al.
Publicado: (2023) -
Liver transplantation in metastatic colorectal cancer: are we ready for it?
por: Ros, Javier, et al.
Publicado: (2023) -
Correction To: Liver transplantation in metastatic colorectal cancer: are we ready for it?
por: Ros, Javier, et al.
Publicado: (2023)